Avanos Medical, Inc. $AVNS Shares Purchased by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL boosted its stake in Avanos Medical, Inc. (NYSE:AVNS) by 509.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 71,893 shares of the company’s stock after acquiring an additional 60,099 shares during the period. Tudor Investment Corp ET AL owned about 0.15% of Avanos Medical worth $831,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of AVNS. Thrivent Financial for Lutherans lifted its holdings in shares of Avanos Medical by 352.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 153,764 shares of the company’s stock valued at $1,778,000 after purchasing an additional 119,760 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Avanos Medical in the 2nd quarter valued at about $1,145,000. Clark Estates Inc. NY grew its stake in Avanos Medical by 58.7% during the 3rd quarter. Clark Estates Inc. NY now owns 783,880 shares of the company’s stock worth $9,062,000 after buying an additional 290,000 shares during the last quarter. Diamond Hill Capital Management Inc. grew its stake in Avanos Medical by 26.0% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 434,661 shares of the company’s stock worth $5,025,000 after buying an additional 89,630 shares during the last quarter. Finally, Cove Street Capital LLC increased its position in Avanos Medical by 430.7% during the third quarter. Cove Street Capital LLC now owns 112,081 shares of the company’s stock worth $1,296,000 after buying an additional 90,963 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Stock Performance

NYSE AVNS opened at $13.73 on Tuesday. The firm has a market cap of $638.58 million, a P/E ratio of -8.69 and a beta of 1.07. Avanos Medical, Inc. has a 52-week low of $9.30 and a 52-week high of $15.68. The business’s 50-day moving average price is $13.85 and its 200 day moving average price is $12.38. The company has a quick ratio of 1.26, a current ratio of 2.15 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The firm had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.70 million. During the same period in the prior year, the business earned $0.43 EPS. The firm’s revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, equities research analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on AVNS shares. Wall Street Zen raised Avanos Medical from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Avanos Medical has an average rating of “Reduce”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.